Neither the nature of the gene defect nor the primary abnormality of the gene product responsible for Duchenne muscular dystrophy (DMD) is known at present, a situation which applies equally to all the human muscular dystrophies. Heterozygote detection is feasible to a limited extent using raised serum creatine kinase and other approaches,' but a combination of X chromosome inactivation and the variability of available tests means that a considerable proportion of carriers cannot be detected reliably. Antenatal diagnosis is similarly not possible at present. 2 We have recently applied recombinant DNA techniques to localise the DMD gene to a small region of the X chromosome. We While these two probes are not sufficiently close to the DMD locus to be used alone for the direct study or prediction of the DMD gene, they demcnstrate the potential of using recombinant DNA sequences for carrier detection and, in certain circumstances, are likely to be of clinical use. We give examples here of specific situations where they can be applied, illustrated by families that we have studied.
Methods
The laboratory techniques involved have been described in detail elsewhere.3 4 DNA is isolated from the leucocytes in a 10 to 20 ml sample of venous blood. After digestion with the restriction enzyme TaqI, electrophoresis, and Southern transfer to a nitrocellulose filter, the DNA is hybridised with the appropriate radiolabelled probe. The For families informative for only one of these RFLPs, the margin of error resulting from cross-over at meiosis is too great for the information to be definitive in isolation. However, when combined with data from existing tests for carrier status, a much more accurate prediction may be obtained. The family shown in fig 3 again provides an example of this situation. Creatine kinase testing on subject 7 gave a result of 46 IU/l (mean of three separate determinations), representing a probability of 0.11 of being a carrier according to our own laboratory range. Combining this information with the previous risk of 0.15 (15%) from linkage data gives a final riskof0-11/0-89 x 0-15/0-85 = 22%.
Discussion
In our studies to establish genetic linkage for DMD, we have relied entirely on persons whose genotype is known with certainty and have omitted possible carriers from the analyses. 4 However, now that linkage is established we can use our gene probes in predicting the genotype of those subjects where it is not certain on genetic grounds.
The margins of error involved for these probes, which are still a moderate distance from the DMD locus, make this approach inappropriate at present for antenatal diagnosis. For carrier detection in female relatives, the use of linkage data in conjunction with more established techniques such as creatine kinase is likely to allow more definite predictions to be made in those persons whose carrier status is at present indeterminate. Clearly, the development of more closely linked probes, in progress at present, will reduce the error, while the detection of additional polymorphisms at high frequency in the population will increase the proportion of informative families.
A particular advantage of using DNA polymorphisms is the lack of ambiguity resulting from X chromosome inactivation, which has seriously hindered all carrier tests based on phenotype. It is also possible to follow both polymorphisms described above using DNA 
